Objective: We evaluated >8500 consecutive, unselected patients with epilepsy and neurodevelopmental disorders who underwent multigene panel testing to determine the average age at molecular diagnosis and diagnostic yield of 70 genes. Methods: We reviewed molecular test results for 70 genes known to cause epilepsy and neurodevelopmental disorders using next generation sequencing (NGS) and exon-level array comparative genomic hybridization (aCGH). A positive result was defined as the presence of 1 or 2 pathogenic or likely pathogenic (P/LP) variants in a single gene, depending on the mode of inheritance of the associated disorder. Results: Overall, 22 genes were found to have a high yield of positive findings by genetic testing, with SCN1A and KCNQ2 accounting for the greatest number of positive findings. In contrast, there were no positive findings in 16 genes. Most of the P/LP variants were sequence changes identified by NGS (90.9%), whereas 9% were gross deletions or duplications detected by exon-level aCGH. The mean age of molecular diagnosis for the cohort was 5 years, 8 months (ranging from 1 week to 47 years). Recurrent P/LP variants were observed in 14 distinct genes, most commonly in MECP2, KCNQ2, SCN1A, SCN2A, STXBP1, and PRRT2. Parental testing was performed in >30% of positive cases. All variants identified in CDKL5, STXBP1, SCN8A, GABRA1, and FOXG1 were de novo, whereas 85.7% of variants in PRRT2 were inherited. Significance: Using a combined approach of NGS and exon-level aCGH, testing identified a genetic etiology in 15.4% of patients in this cohort and revealed the age at molecular diagnosis for patients. Our study highlights both high-and lowyield genes associated with epilepsy and neurodevelopmental disorders, indicating which genes may be considered for molecular diagnostic testing.
| INTRODUCTION
Epilepsy and neurodevelopmental disorders (NDD) that include epilepsy as a defining feature are some of the most common disorders affecting infants and children worldwide. Overall, at least 0.8% of the population is affected with epilepsy and 3%-5% of children suffer from NDD. [1] [2] [3] Epilepsy is defined as the occurrence of (1) at least 2 unprovoked seizures occurring >24 hours apart; (2) 1 unprovoked (or reflex) seizure with the probability of further seizures similar to the general recurrence risk (at least 60%) after 2 unprovoked seizures, occurring over the next 10 years; or (3) a diagnosis of an epilepsy syndrome. 4 There are many causes of epilepsy, including trauma, perinatal injury, stroke, postinfectious lesions, tumors, and genetic forms that can include structural brain anomalies and metabolic disease. 3, 5 The underlying etiology is unknown in 40%-50% of cases of epilepsy, although it has been estimated that approximately 30% of epilepsy is genetic. 5 According to a recent study, an underlying genetic cause can be identified in~40% of individuals with early onset epilepsy. 6 Clinical genetic testing capabilities for epilepsy and NDD have expanded in recent years and include different technologies and strategies. Next generation sequencing (NGS) has revolutionized the ability to simultaneously analyze multiple genes accurately and efficiently. This has allowed laboratories to create multigene panels for many clinical indications. Combining NGS with exon-level deletion/duplication analysis permits detection of most diseasecausing variants in epilepsy and NDD genes in a single test, and thus provides an effective diagnostic tool for patients with epilepsy and NDD.
Here, we review the diagnostic outcomes of 70 genes tested by NGS and array comparative genomic hybridization (aCGH) for an unselected cohort of 8565 patients with epilepsy and NDD. We report the frequency, type, and inheritance pattern of pathogenic or likely pathogenic (P/LP) variants in well-established and newly emerging epilepsy and NDD-related genes. Of the 70 genes evaluated, 22 had a high diagnostic yield and 16 had a low diagnostic yield. Among patients with positive diagnostic findings, the mean age at molecular diagnosis varied from 3 months to 9 years, depending on the gene. We found that P/LP variants in some high-yield genes could be inherited from affected or unaffected parents, whereas P/LP variants in other genes were always observed de novo, thus influencing recurrence risk.
| MATERIALS AND METHODS

| Patients
The cohort included 8565 consecutive individuals with epilepsy and/or NDD submitted to our molecular diagnostic laboratory for genetic testing using 1 of 5 epilepsy gene panels, as deemed appropriate by the ordering clinician, from December 2011 through December 2015. Informed consent for genetic testing was obtained from all individuals undergoing testing.
| Age at molecular diagnosis
Date of birth was received for the majority of patients and used to determine the mean and median age at which testing was completed for each individual. For positive cases, the age at testing was used to calculate the mean and median ages at molecular diagnosis for the panels and genes reviewed in this study. For the mean age at molecular diagnosis for individual genes, outliers were identified and excluded using the interquartile range method and an adjusted mean was recalculated.
| Gene selection for genetic testing panels
We evaluated 70 genes reported to cause different genetic forms of epilepsy and NDD on a total of 5 different panels. Genes were assigned to panels specific for age of onset and phenotype based on the typical age of onset of epilepsy and the major phenotype associated with the gene according to literature review. The following targeted panels were performed (Table S1 ): infantile onset epilepsy (up to 53 genes), childhood onset epilepsy (up to 50 genes), infantile-STAT epilepsy (18 genes with a focus on very early onset epilepsy and/or disorders with treatment implications; testing included an expedited turnaround time), progressive myoclonic epilepsy/Lafora disease/neuronal ceroid lipofuscinoses (PME) (up to 17 genes), and a comprehensive panel containing all 70 genes from the targeted panels (Table S1 ).
| NGS
Targeted exons were amplified from genomic DNA using either multiplex polymerase chain reaction (Raindance
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• CNVs account for~9% of positive results and make a significant contribution to the overall diagnostic yield of multigene panels Technologies, Lexington, MA, USA) or RNA probe capture using a custom Agilent SureSelect kit (Agilent Technologies, Santa Clara, CA, USA) to produce DNA libraries for NGS. NGS data were generated, and sequence variants were identified, filtered, and evaluated with a custom bioinformatics pipeline as previously described. 7 Regions of interest were defined as coding exons, AE20 base pairs (bp) of flanking intronic sequence of both coding and noncoding exons, and 20 bp of 5 0 and 3 0 untranslated region sequence. An average coverage depth of at least 12009 was obtained for all panels.
Positions within the regions of interest covered with <159 read depth were sequenced by conventional di-deoxy DNA sequencing using an ABI3730 sequencer (Life Technologies, Carlsbad, CA, USA) and standard protocols. Pathogenic (P) variants, likely pathogenic (LP) variants, variants of uncertain significance (VUS), and in rare instances likely benign variants were confirmed by conventional di-deoxy DNA sequence analysis and reported.
| Copy number variant detection
Copy number variations (CNVs) were also evaluated for all patients using exon-level aCGH. Most targeted exons were covered by 3-7 probes within the exon boundaries or 250 bp of flanking sequence. Additional probes were added as described previously. 8 All P/LP or VUS CNVs were confirmed by multiplex ligation-dependent probe amplification, quantitative polymerase chain reaction, or repeat aCGH. Figure 1A ). Although 5.4% (71/1315) of positive cases had pathogenic findings in >1 gene, the majority of these cases (90.1%; 64/71) had a single molecular diagnosis in addition to being a carrier of a P/LP variant in a gene associated with an AR disorder. Cases with dual diagnoses were observed very rarely (0.5%; 7/1315) in this cohort. The majority of positive findings were identified in 22 genes (Table 1) , each contributing to 1% or more of the total positive findings and referred to as a high-yield gene. SCN1A (24.8%; 322/1299) and KCNQ2 (13.2%; 159/1207) accounted for the highest number of positive cases (Table 1) . When reviewed in the context of inheritance, CDKL5 had the highest positive yield of genes associated with XL disorders and TPP1 for AR disorders (Table 1) . Our evaluation further supports growing evidence that several genes (ATP6AP2, CACNB4, CHRNA2, DNAJC5, EFHC1, MAGI2, and SRPX2) have a low diagnostic yield, as no P/LP variants were reported in these genes in this cohort (Table 1 ).
| Variant analysis and interpretation
| Age at molecular diagnosis
The mean age at molecular diagnosis for individuals with a positive finding in this cohort was 5 years, 8 months (median = 3 years, 5 months), but ranged from 1 week to 47 years (see Table 2 ). Among patients with positive diagnostic results, the age at testing varied greatly depending on the disease gene. The only genes with a mean age of molecular diagnosis < 1 year were KCNJ10, PNPO, TBC1D24, PRRT2, and KCNQ2 (3, 7, 7, 8, and 9 months, respectively). In contrast, the mean age at molecular diagnosis was 3-6 years for several genes typically associated with early onset seizures (ALDH7A1, ARX, CDKL5, SCN8A, SLC2A1, and STXBP1). This finding indicates that there may be a delay of months to years in making a molecular diagnosis for patients with pathogenic variants in these genes.
| Spectrum of P/LP variants identified
Overall, 1414 P/LP variants were identified in 1315 positive cases, including 1277 sequence-based changes, 5 ARX repeat expansions, and 132 CNVs ( Figure 1B ). P/LP variants were identified by NGS in the majority of positive cases (90.3%; 1277/1414), although 9.3% (132/1414) of pathogenic variants were CNVs detected by exon-level aCGH. Of the sequence-based changes, 719 were missense (56.3%; 719/ 1277), 162 nonsense, 268 frameshift, and 110 splicing variants, in addition to 18 small in-frame insertions/deletions ( Figure 1B , Table S4 ). Five patients had both a sequencebased change and a CNV in the same gene, resulting in an AR disorder (0.4%, 5/1315). One patient (0.1%, 1/1315) had a P/LP sequence variant causing an AD disorder as well as a pathogenic CNV in another gene associated with a second AD disorder (dual diagnoses).
In total, 173 CNVs were identified in this cohort, including 143 (82.7%) deletions and 30 (17.3%) duplications (Table 3) . CNVs were identified in several genes not previously reported to have exon-level deletions or duplications (GABRG2, MFSD8, PNKP, SPTAN1, and TPP1; Recurrent P/LP variants, defined as having been observed in 3 or more unrelated individuals in the cohort, were identified in 15 genes associated with AD or XL disorders (Figure 2 , Table S2 ). The most common P/LP variant in our cohort was c.649dupC in PRRT2, observed in 64.4% (38/59) of cases with a pathogenic PRRT2 variant. This gene causes several disorders, but is most frequently associated with paroxysmal kinesigenic dyskinesia, a seizure and movement disorder that resolves in adulthood and is often inherited from a parent with a history of benign neonatal or childhood seizures. 10 Recurrent P/LP variants were found in several genes (see Table S2 ). Seventeen percent of P/LP variants (5/ 29) in MECP2 and 10.2% of P/LP variants in KCNQ2 (11/ 108) were recurrent and accounted for 34.8% (16/46) and 29.6% (47/159) of MECP2-and KCNQ2-positive cases, respectively. Although only 5.0% (13/258) of P/LP variants in the SCN1A gene were considered recurrent, these variants accounted for 14.9% (48/322) of SCN1A-positive cases. Similar findings were observed for the SCN2A and STXBP1 genes ( Figure 2 , Table S2 ). In contrast, P/LP variants in FOXG1 (16 different variants), GABRG2 (19), GRIN2A (18), SLC2A1 (42), TCF4 (6), and ZEB2 (9) were mostly unique.
| De novo versus inherited pathogenic variants
Targeted parental testing was recommended for all probands with positive results, and subsequently performed at A combination of de novo and inherited P/LP variants was observed in 8 other genes (Figure 2 , Table S3 ). For example, 73.3% (11/15) of P/LP variants in GABRG2 were de novo, whereas 26.7% (4/15) were inherited. In SCN1A, 75.3% (73/97) of P/LP truncating and missense variants were found to be de novo, whereas the remaining 24 missense variants were inherited (Figure 2 ). In contrast, the PRRT2 gene had very few de novo P/LP variants and a high rate of inherited variants (85.7%; 6/7). Limited information was available for other genes, as parental testing was completed less often. For GRIN2A (7/8), TSC1 (2/3), and SLC2A1 (12/14), most disease-causing variants were de novo ( Figure 2 , Table S3 ). For MECP2, P/LP variants were typically de novo, as heterozygous females and hemizygous males can be affected. 12 However, we identified 2 individuals with inherited late truncating variants in exon 4, consistent with other studies. 12 
| DISCUSSION
Previous studies show that NGS of multiple disease-related genes is an efficient tool for the diagnosis of epilepsyrelated disorders. [13] [14] [15] This finding is particularly true for early onset epileptic encephalopathy, which has been reported to have a higher proportion of monogenic causes than other epilepsies. 16 Additionally, relatively high rates of mosaicism have been reported in many genes associated with epilepsy, supporting the need for NGS as opposed to Sanger sequencing for diagnostic testing of these genes. 7 Positive diagnostic yields of multigene epilepsy panels are reported to range from 18% to 28%, indicating that this type of testing has high clinical utility for individuals with epilepsy and/or NDD. 6, 14, 15, 17 The positive diagnostic rate reported for this cohort was 15.4%. The unselected nature of our cohort likely contributes to the lower positive rate in comparison to previously reported studies, which utilized more homogeneous cohorts with well-defined phenotypes.
Our results support the growing body of literature finding that SCN2A, CDKL5, KCNQ2, FOXG1, MECP2, SCN1A, STXBP1, PCDH19, and SLC2A1 are high-yield genes for epilepsy and NDD. 15, 16, 18, 19 We provide further evidence that the SCN8A, GRIN2A, and GABRG2 genes are also high-yield genes for this phenotype. 16, [18] [19] [20] We also identified several genes with low diagnostic yield for epilepsy and NDD, some of which are rare causes of epilepsy and were simply not observed in this cohort (CHRNA2, CSTB, CTSD, DNAJC5, FOLR1, GATM, GOSR2, MAGI2, NRXN1, SLC25A22, and PRICKLE1) and others that have been questioned in the literature (including ATP6AP2, CACNB4, EFHC1, and SRPX2). For example, the original family reported to have an SRPX2-related disorder was later reported to have a pathogenic variant in the GRIN2A gene, with subsequent publications providing further evidence against the association of the SRPX2 gene with epilepsy. 21, 22 For the EFHC1 and ATP6AP2 genes, previously published disease-associated variants and protein-truncating variants were subsequently identified in healthy adult controls, raising doubt about their pathogenicity. [22] [23] [24] Very little functional evidence has been reported for the CACNB4 protein, and its role in epilepsy remains poorly understood. 25, 26 Our results suggest that the ATP6AP2, CACNB4, EFHC1, and SRPX2 genes have low diagnostic yield, and variants in these genes should be reported with caution, because further research is needed to determine whether these genes are associated with epilepsy or NDD. Review of the patients' age at the time of genetic testing revealed interesting insights and suggested that a molecular diagnosis is often delayed for patients with epilepsy. The infantile onset epilepsy panel is designed for individuals with seizure onset before age 2 years; however, the mean age of molecular diagnosis for patients referred for this panel was 3 years, 10 months. Among patients with positive findings in genes with well-described infantile onset seizures (ALDH7A1, ARX, CDKL5, KCNQ2, PNPO, SCN8A, and STXBP1), mean age at molecular diagnosis ranged from 3 months to 5 years. For many epilepsies, knowledge of the specific genetic etiology can provide essential information about prognosis and influence decisions regarding treatment and management. Making an early molecular diagnosis can also end the genetic odyssey, allow for recurrence risk counseling, guide participation in gene-specific clinical trials, and provide families with the opportunity to interact with support groups or advocate for research. Recently, Berg et al. 6 suggested that all patients with early life epilepsies should have genetic testing incorporated into the initial evaluation when the clinical diagnosis is made. However, our data suggest that genetic testing is not typically performed at the time of seizure onset. This study further demonstrates that parental testing provides important information for molecular diagnosis of epilepsy-related disorders. Parental testing may assist in assessing pathogenicity of a variant and recurrence risk for the family. Parental testing showed that all pathogenic variants in 5 genes (FOXG1, CDKL5, GABRA1, SCN8A, and STXBP1) occurred de novo, corresponding with the severe, infantile onset presentation of their associated disorders, thus establishing a relatively low recurrence risk for these families. Eight other genes associated with AD and XL F I G U R E 2 Rates of de novo, inherited, and recurrent variants in selected genes. Genes colored in red indicate high rates of de novo pathogenic or likely pathogenic (P/LP) variants, and those in green indicate lower rates of de novo P/LP variants. The light gray box denotes the number of recurrent variants identified in that gene. The dark gray box denotes the percentage of cases that had a recurrent variant, including the number of cases with a recurrent variant and the number of positive cases in that gene in parentheses. In the rightmost column, dark blue bars indicate the number of cases with a recurrent variant and light blue bars indicate the number of total positive cases for that gene disorders showed a high rate of de novo variants (73%-90%; Figure 2 , Table S3 ), which is consistent with the findings in previous studies. 16, 18, 27, 28 It is important to note that P/LP variants in these genes were found to be inherited in 10%-27% of cases, highlighting a notable recurrence risk in these families.
In conclusion, this study reports on the outcome of genetic testing in >8500 patients with epilepsy, highlights both high-and low-yield genes for epilepsy and NDD, and further supports the utility of parental testing. Specifically, we demonstrate that multigene panels utilizing NGS and deletion/duplication analysis to evaluate high-yield genes are a valuable diagnostic tool for individuals with epilepsy and NDD. Ninety percent of the positive findings in this cohort were identified in 22 high-yield genes, defined as contributing to ≥1% of the total positive cases reported. These genes could be considered critical in the evaluation of individuals with epilepsy and NDD. Of note, the rate of gene discovery for genetic epilepsies has been significant in recent years and additional potentially high-yield genes have been reported recently (ie, DEPDC5, KCNT1, IQSEC2, KIAA2022, and SLC6A1). [29] [30] [31] Based on our results and limited published evidence, the CACNB4, EFHC1, SRPX2, and ATP6AP2 genes appear to be lowyield and variants in these genes should be reviewed cautiously. When variants are identified in a proband, parental testing should be considered to clarify the clinical significance of the variant and determine recurrence risk for the family. Lastly, it appears that many patients in this cohort were referred for genetic testing months to years after onset of seizures. However, an earlier molecular diagnosis could improve outcomes for patients, as some gene-specific treatments exist and more are likely to be developed with the advent of precision medicine.
